# Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)

> **NCT05593614** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AlgoTherapeutix** · enrollment: 276 (actual)

## Conditions studied

- Chemotherapy-induced Peripheral Neuropathy

## Interventions

- **DRUG:** ATX01 10%
- **DRUG:** ATX01 15%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05593614
- **Lead sponsor:** AlgoTherapeutix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-28
- **Primary completion:** 2024-09
- **Final completion:** 2024-09
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05593614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05593614, "Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05593614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*